plasebo

Keunggulan tirzepatide milik Lilly dibandingkan dengan plasebo untuk penyelesaian MASH, dan lebih dari setengah pasien mencapai perbaikan dalam fibrosis pada 52 minggu

oleh

Zepbound. Talk to your healthcare provider for more information. Please see the full Prescribing Information, including Medication Guide, for Zepbound at www.zepbound.com. About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than … Baca Selengkapnya

TAGRISSO ® (osimertinib) mengurangi risiko kemajuan penyakit atau kematian sebesar 84% pada pasien kanker paru-paru Stadium III EGFR-mutasi yang tidak dapat dioperasi dibandingkan dengan plasebo dalam uji coba Fase III LAURA.

oleh

The LAURA Phase III trial results represent a significant advancement in the treatment of Stage III EGFR-mutated non-small cell lung cancer. TAGRISSO demonstrated a remarkable improvement in progression-free survival, reducing the risk of disease progression or death by 84% compared to placebo. This groundbreaking data establishes TAGRISSO as a new standard of care for patients … Baca Selengkapnya